Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

Fineline Cube Dec 14, 2025
Company Deals

InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program

Fineline Cube Dec 14, 2025
Company Deals

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery

Fineline Cube Dec 13, 2025
Company Deals

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs

Fineline Cube Dec 13, 2025
Company Deals

B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline

Fineline Cube Dec 13, 2025
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025
Company Drug

Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial

Fineline Cube Dec 14, 2025
Company Drug

Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment

Fineline Cube Dec 14, 2025
Company Deals

Tongling Bionic Raises Hundreds of Millions in Series B Financing for Cardiopulmonary Equipment Development

Fineline Cube Jul 19, 2022

Anhui Tongling Bionic Technology Co., Ltd, a Chinese developer of cardiopulmonary circulatory assist equipment, has...

Company Drug

Sesen Bio Terminates Vicineum Development After FDA Talks, Citing Phase III Costs

Fineline Cube Jul 19, 2022

Sesen Bio Inc. (NASDAQ: SESN) announced the termination of clinical development for Vicineum (VB4-845), its...

Company Medical Device

Huadong Medicine’s GFR Monitoring System Accepted by NMPA for Review

Fineline Cube Jul 19, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a glomerular...

Company Drug

Roche’s Chugai Launches Edirol in China for Postmenopausal Osteoporosis

Fineline Cube Jul 19, 2022

Swiss pharma giant Roche’s subsidiary Chugai Pharmaceutical Co Ltd has officially launched Edirol (eldecalcitol), an...

Company Drug

Humanwell Healthcare’s RFUS-144 Wins NMPA Approval for Pruritus Clinical Study

Fineline Cube Jul 19, 2022

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its Category 1 drug RFUS-144...

Company Deals

Brii Biosciences Partners with Huarun Medicine to Commercialize COVID-19 Antibody Cocktail in China

Fineline Cube Jul 19, 2022

China-based Brii Biosciences Ltd (HKG: 2137) announced a partnership with Huarun Medicine Business Group International...

Company Drug

Hengrui Medicine Launches Revelutamide for Metastatic Prostate Cancer in China

Fineline Cube Jul 19, 2022

Hengrui Medicine has launched revelutamide (SHR3680; trade name: Erion), China’s homegrown innovative androgen receptor (AR)...

Company Deals

Chongqing Lummy Pharma Cancels YZY Biopharma Y400 Partnership, Secures Compensation

Fineline Cube Jul 19, 2022

China’s Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) announced the termination of its strategic partnership...

Drug

HutchMed Initiates Phase I Study of CD47 Monoclonal Antibody HMPL-A83 in China

Fineline Cube Jul 19, 2022

China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase I clinical study...

Company Deals

Grand Pharma Acquires Stake in Xeltis and Licenses aXess for Hemodialysis in Greater China

Fineline Cube Jul 19, 2022

China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced the acquisition of an 11% stake in...

Company Deals

Fermion Secures Series B Financing to Advance AI-Driven Drug Development

Fineline Cube Jul 18, 2022

Guangzhou-based AI biotech Fermion has raised over RMB100 million ($14.8 million) in a Series B...

Company Deals

Biotree Raises $14.8M in Series A Financing to Expand Multi-Omics Platform

Fineline Cube Jul 18, 2022

Shanghai-based multi-omics specialist Biotree has raised nearly RMB100 million ($14.8 million) in a Series A...

Company Drug

Kexing Pharmaceutical’s SHEN26 COVID-19 Drug Receives NMPA Approval for Clinical Trials

Fineline Cube Jul 18, 2022

China-based Kexing Pharmaceutical (SHA: 688136) announced that its oral small-molecule COVID-19 drug SHEN26, co-developed with...

Company Deals Digital

WeDoctor Partners with Jinan Innovation Zone to Launch Dual Healthcare Platform

Fineline Cube Jul 18, 2022

China-based WeDoctor Holdings Ltd, a Tencent-backed online medical service platform, has partnered with Jinan Innovation...

Company Drug

ImmuneOnco’s IMM2902 Receives FDA Fast-Track Designation for CD47/HER2 Targeting

Fineline Cube Jul 18, 2022

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced that the U.S. Food and Drug Administration (FDA) has...

Policy / Regulatory

VBP Round 7 Drug Procurement Contract Awards Top Winners Revealed

Fineline Cube Jul 18, 2022

China’s 7th national Volume-Based Procurement (VBP) round concluded with winning bids for 60 drug products...

Company

Merck KGaA Launches Uptune Program in Asia, Offers Startups Up to €100,000

Fineline Cube Jul 18, 2022

Germany-based life sciences giant Merck KGaA has launched the Uptune program in Asia, offering up...

Company Drug

Pfizer Launches Cejemly in China for Stage III NSCLC, Expands Immunotherapy Reach

Fineline Cube Jul 18, 2022

Pfizer announced the commercial launch of Cejemly (sugemalimab) in China for Stage III non-small cell...

Company Deals

Sihuan Pharma to Sell Generic Drug Businesses, Shift Focus to Aesthetics and Biologics

Fineline Cube Jul 18, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced plans to divest a portion of...

Company Drug

Luye Pharma’s Lurbinectedin Receives Hainan Approval for SCLC Treatment

Fineline Cube Jul 18, 2022

China-based Luye Pharma Group (HKG: 2186) announced approval from the Hainan Medical Products Administration for...

Posts pagination

1 … 579 580 581 … 597

Recent updates

  • Peijia Medical Wins NMPA Approval for TaurusTrio TAV, First Transfemoral System for Aortic Regurgitation
  • Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal
  • Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial
  • Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment
  • InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Peijia Medical Wins NMPA Approval for TaurusTrio TAV, First Transfemoral System for Aortic Regurgitation

Company Deals

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

Company Drug

Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial

Company Drug

Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.